1. Field of the Invention
The invention relates to a method for selectively labeling S-nitrosylated proteins with a fluorescent tag. The method offers femtomolar sensitivity for the detection, quantification, in situ visualization, and a means for site-specific identification of nitrosylation events
2. Background Information
Protein S-nitrosylation, a reversible post-translation modification of cysteines, affects many cell signaling pathways1,2. Emerging evidence suggests that dysregulation of this redox-sensitive modification is a marker of, or contributes to the pathophysiology of many disease processes including arthritis, pre-eclampsia, asthma, and stroke3,4.
Rapid and global detection of biologically relevant nitrosylated proteins would help identify novel NO signaling pathways and molecular mechanisms of many redox-sensitive pathophysiologies5,6. The biotin switch assay2 has been used to study S-nitrosylation in a variety of proteomes7-10. It involves three steps aimed at replacing the cysteine linked nitrosothiol with a biotin tag at the S-nitrosylation sites: (1) block free thiols, (2) selectively reduce S-nitrosylated cysteines, and (3) biotinylate the newly released cysteine thiols (
Accordingly a new and improved method for the detection and identification of nitrosylated proteins is desirable.
We describe herein a modification of the biotin switch assay; Selective Fluorescent Labeling Of S-nitrosothiols (S-FLOS,
Accordingly, a method is provided for detecting and/or identifying S-nitrosylated protein in a sample, comprising the steps of
a) treating the sample with an alkylthiolating agent conditions such that free thiol groups in the protein become alkylthiolated;
b) removing unreacted alkylthiolating agent from the sample;
c) treating the sample with a reducing agent such that nitrosothiol bonds on the protein are reduced to form new free thiol groups;
d) treating the sample with a maleimide-derivatized fluorescent dye under conditions such that free thiol groups become labeled with said dye to form detectably labeled protein;
e) detecting/identifying detectably labeled protein, wherein said detectably labeled protein corresponds to S-nitrosylated protein contained in said sample.
The method results in a treated sample that can be further processed to quantify and map sites of S-nitrosylation within the S-nitrosylated protein, e.g. by the use of gel electrophoresis, liquid chromatography, mass spectrometry, or cytohistochemistry.
In one embodiment, the alkylthiolating agent is methyl methanethiosulfonate (MMTS). Additional suitable alkylthiolating agents will be known to those of skill in the art.
The maleimide-derivatized fluorescent dye is typically selected from the group consisting of Cy-maleimide dyes, Alexa Fluors, Texas Red, and BODIPY. Other suitable maleimide-derivatized fluorescent dyes known in the art may also be used, and can be tested for suitability without undue experimentation. In particular, Cy3-maleimide dye and/or Cy5-maleimide dye are known to produce superior results.
Any suitable reducing agent that is known to those of skill in the art can be used in the method, e.g. ascorbate.
Sodium dodecyl sulfate (SDS) and/or other suitable detergent(s) can be used along with the other reagents to ensure access of alkylthiolating agent to buried cysteines. Under the conditions used, alkylthiolating agent does not react with nitrosothiols or preexisting disulphide bonds.
Also provided is a kit for the detection/identification/quantification of S-nitrosylated protein and sites of S-nitrosylation within the S-nitrosylated protein in a sample. The kit comprises suitable reagents for carrying out the methods disclosed herein, for example, a maleimide-derivatized fluorescent dye (e.g. Cy-maleimide dyes, in particular Cy-3 and Cy-5, Alexa Fluors, Texas red, and BODIPY), and any combination of the following: an alkylthiolating reagent, a reducing agent (e.g. ascorbate), a standard sample comprising at least one protein substrate, a column cartridge for enriching Cy labeled peptides, and instructions and/or software to quantify or map S-nitrosylation sites. The kit may also comprise reagents for further processing, e.g. for 2 dimensional gels, mass spectroscopy, etc.
Methods disclosed herein have several advantages over previously used methods. First, false positives are inherently reduced. Second, fluorescent label remains present and is compatible with all protein separation techniques, including 2D gel electrophoresis, and provides means to directly identify, detect and quantify changes in S-nitrosylation on individual proteins in complex mixtures in a true multiplex format. Furthermore, the features of S-FLOS, two sample multiplexing and the ability to analyze samples by gel electrophoresis, liquid chromatography, mass spectrometry, and cytohistochemistry under reducing conditions, makes the S-FLOS method uniquely different from all other published methods. S-FLOS is a powerful cross-platform analytical and quantitative technique for S-nitrosylation and can be readily modified for analyzing other modifications of cysteines. In addition, S-FLOS has the advantage of mapping and quantify changes in nitrosylation at specific cysteines within a protein.
The methods disclosed herein can be used, or example, to screen for potential drugs which are useful in modulating protein nitrosylation, and/or to identify proteins which are affected by nitrosylation. For example, a test compound can be contacted with a biological sample and the effect of the test compound on the nitrosylation of proteins within the biological sample can be determined, e.g. by comparing nitrosylation of proteins within a biological sample to the nitrosylation of proteins within a control sample which has not been treated or contacted with the test compound. An increase or decrease in the amount of nitrosylation observed in the test sample can be used as an indication of potential usefulness as a drug for modulating protein nitrosylation. Drugs identified in this manner are expected to be useful for modulating such processes as apoptosis, neurotoxicity, neurotransmitter release, cellular proliferation, smooth muscle relaxation, and differentiation. Similarily to drug screening, these methods can be used to screen for diseases the affected by the nitrosylation or for nitrosylation state markers indicating onset or prognosis of reoxiditive related diseases.
While specific examples have been provided, the description herein is illustrative and not restrictive. Any one or more of the features of the described embodiments can be combined in any manner with one or more features of any other embodiments in the present invention. Furthermore, many variations of the invention become apparent to those skilled in the art upon review of the specification. The scope of the invention should, therefore, be determined not with reference to the description herein, but instead should be determined with reference to the appended claims along with their full scope of equivalents.
This application claims priority to U.S. provisional patent application No. 60/845,944, filed Sep. 20, 2006, which is incorporated herein by reference.
Fluorescence intensity for lysozyme was not detected, suggesting that lysozyme is not nitrosylated under these conditions; C) BSA-SNO content for each dose was quantified using an amperometric assay for total NO content. S-FLOS intensities were calculated using ImageQuant and normalized to the protein load based on densitometry silver stain images. S-FLOS can detect femtomole levels of SNO. Error bars represent ± standard deviation for three replicates from 3 Cy3- and 3 Cy5-labeled samples. Lower panel shows gel images of BSA-SNO content using S-FLOS; D) S-FLOS was used to determine endogenous nitrosylation in WT and NOS1 knockout mice (left panels). Both Cy3 and Cy5 show similar labeling with very low background in ascorbate deficient lanes (-Asc). Protein load was visualized using silver staining (right panels).
By “alkylthiolating agent” is meant an agent that forms alkylthiol groups when reacted under suitable conditions with free thiol groups. Alkylthiolating agents contain straight or branched chain lower alkyl (C1-C6) groups that may be derivatized or functionalized, and may contain regions of unsaturation, for example MMTS. The blocking agent is preferably removed from the test sample prior to the step of the detectable tagging. MMTS, for example, can be removed by acetone precipitation (MMTS remains in the supernatant) or by subjecting the test sample to a spin column or spin filter.
Unless indicated otherwise by context, by “sample” or “test sample” is meant any sample which may be suitably tested using the methods disclosed herein. Test samples can be e.g. in the form of any biological sample, for example, crude, purified or semipurified lysates of tissues that potentially comprise nitrosylated proteins, e.g. brain, peripheral nerve, muscle, blood vessels, blood cells, liver, etc.
By “reducing agent” is meant a compound such as ascorbate that reduces nitrosothiol bonds on the protein to form new free thiol groups. Agents such as Cu2+ or Hg2+ may also be used. Care must be taken to remove these, as these metals can interfere with the labeling step.
Animals: NOS1 knockout and wild type mice (9-11 weeks old) were used in this study and purchased from Jackson Labs. The mice were anesthetized and perfused with normal saline to remove blood. The brains were then dissected, snap frozen, and stored at −80° C. until all samples were collected (2 days). The samples were homogenized in 50 mM Tris-HCl buffer (pH 7.5) containing protease inhibitors (Roche) and 1 mM neocuproine (Sigma) and used immediately.
S-FLOS method for purified proteins: 100 μg protein were incubated with 20 mM methyl methanethiosulfonate (MMTS) at 50° C. to block the free cysteines. Excess GSNO and MMTS were removed by cold acetone precipitation and proteins were redissolved in 100 μl Reducing Buffer (50 mM TRIS-HCl pH 7.4, 4% CHAPS, 5 mM ascorbate. After a 1 h incubation, the reduced proteins were buffer exchanged in 120 μl Labeling Buffer (50 mM TRIS-HCl pH 7.0, 7 M Urea, 4% CHAPS) using protein desalting columns (Pierce). The reduction and labeling steps were performed sequentially because ascorbate sometimes interfered with the Cy-dye labeling step. 5 μl of each sample were labeled with 10 pmol of Cy3- or Cy5-maleimide, resolved using SDS-PAGE and scanned to determine fluorescence intensities (Typhoon scanner, GE Healthcare). The entire assay was performed in the dark. The gels were post stained using colloidal coomassie blue and scanned to determine protein loads using densitometry (UMAX PowerScan III).
S-FLOS method for cell lysates/tissue homogenates: 100 μg total protein were blocked and reduced as described above. After buffer exchange into Labeling Buffer, protein concentration was determined either using the BioRad protein assay reagent or using 2D-gel protein Quant kit (GE Healthcare). 12.5 μg of sample was then labeled with 40 pmol of either Cy3- or Cy5-maleimide. The samples were then either resolved using SDSPAGE (
2D Gel electrophoresis: 12.5 μg each of the Cy3 and Cy5 labeled samples were mixed and buffer exchanged into 120 μl of Rehydration Buffer (8 M Urea, 4% CHAPS, 0.2% DTT, 0.0002% bromophenol blue). 1.8 μl of ampholytes (pH 4-7 IPG buffer, GE Healthcare) were added, and the proteins were resolved on a 7 cm pH 4-7 IPG strip (GE Healthcare) followed by 4-12% gradient SDS-PAGE (NuPage, Invitrogen). The gels were run in the dark. Gels were imaged on a Typhoon scanner and post-stained with silver. The silver stained gel was imaged on a UMAX PowerScan III. Indicated spots were excised for identification using MS.
In situ labeling of S-nitrosothiols: IFNγ/LPS-stimulated and unstimulated RAW264.7 cells grown on coverslips were fixed in 3% paraformaldehyde and permeabilized with 0.05% Triton X-100. After blocking free thiols with 20 mM MMTS, the coverslips were washed in Wash Buffer (PBS containing 0.5% v/v Tween-20) and the SNOs reduced using 5 mM ascorbate. The cells were then rinsed in Wash Buffer and incubated with 10 μM Cy3 in Labeling Buffer at 37° C. for 30 min. All steps were performed in the dark. The samples were washed in Wash Buffer and fluorescence images were acquired using a Nikon Eclipse TE200 microscope and an internally-cooled 12-bit CCD camera (CoolSnapHQ, Photometrics, Tucson, Ariz.). Images were collected using OpenLab software (Improvision, Lexington, Mass.). Nuclei of cells were labeled with DAPI (Invitrogen) and imaged using fluorescence microscopy. Images of S-FLOS (Cy3, red) were merged with images of nuclei (blue).
Amperometric detection of S-nitrosothiols: Absolute levels of S-nitrosothiols were determined using an amperometric NO probe (WPI Inc). In brief, the ISO-NOP70L probe was polarized per vendor's protocol. GSNO was used to calibrate the probe. 200 μg BSA were treated with increasing doses of GSNO for 30 min in dark. Excess GSNO was removed by an acetone precipitation step followed by desalting (Pierce) and recovered into 120 μl. Protein concentration was determined (BioRad Protein Assay reagent). BSA-SNO levels were determined amperometrically using 100 μg of protein.
Nitrite accumulation in cell culture media: Nitrite accumulation was determined using the Nitrite/Nitrate assay kit (Calbiochem) following manufacturer's instructions.
Protein Identification: Silver stained protein bands or spots excised from gels were destained using 30 ul of 1:1 mixture of 30 mM potassium ferricyanide and 100 mM sodium thiosulfate according to Gharahdaghi et al., 1999 Electrophoresis 20, 601-5) and digested with trypsin (sequencing grade, Promega) in 20 mM ammonium bicarbonate at 37° C. overnight as previously described (Shevchenko et al., 1996 Anal Chem 68, 850-8). Extracted peptides were fractionated on a 5-40% acetonitrile gradient in 0.1% formic acid over 25 min at 300 nl/min on a 75 um×100 mm column with a 8 um emitter (New Objectives, Inc., www.newobjective.com) and packed with 5 μm, 120 Å C18 beads (YMC ODS-AQ, Waters Corp., www.waters.com). Eluting peptides were analyzed by collision-induced dissociation (CID) using nanoLC tandem mass spectrometry analysis on a QSTAR/Pulsar (Applied Biosystems/MDX Sciex, home.appliedbiosystems.com) interfaced with an Eksigent 2D nano-LC system (www.eksigent.com). Survey scans were acquired from m/z 350-1200 with up to three precursors selected for MS/MS using a dynamic exclusion of 30 s. A rolling collision energy was used to promote fragmentation. Peptide sequences were identified by screening the fragmentation data against the NCBI non-redundant database using in-house Mascot server and Mascot Daemon as an interface. Peptides with scores higher than Mascot's calculated 95% confidence probability threshold were considered reliable peptide sequences and are listed below for proteins in Table 1. Proteins with two or more reliable peptides were considered significant protein identifications. Table 1 shows a partial list the proteins identified from the 2D gel in
S-FLOS may use identical blocking and reduction steps as the biotin switch assay (
For proof of principle, we studied the exogenous nitrosylation of a mixture of four proteins by the NO donor, S-nitrosoglutathione (GSNO) (
We next used this method to quantify exogenously nitrosylated BSA and determined the sensitivity of the method. An amperometric probe (WPI Inc), calibrated with GSNO, was used to quantify absolute levels of BSA S-nitrosylation and detected basal nitrosylation in BSA. The S-FLOS method clearly detected changes in BSA nitrosylation at very low GSNO concentrations (<3 μM), and even detected basal nitrosylation of BSA (
We next compared S-FLOS with the biotin switch assay using IFNγ/LPS to induce NOS2 in RAW264.7 cells (
We also compared the S-FLOS method with existing fluorescent staining methods12,13. To compare its efficacy to published staining methodsg, we used S-FLOS to visualize S-nitrosylated proteins in fixed and permeabilized stimulated vs unstimulated RAW264.7 cells (
We next used S-FLOS to determine basal nitrosylation in the brain homogenates of wild-type compared to NOS1−/− mice. Samples were subjected to S-FLOS and resolved using SDS-PAGE (see supplement for detailed methods). Differences in signal intensity between the wild-type and NOS1 knockout mice were clearly distinguished (
We then determined the capability of S-FLOS to quantify endogenous protein S-nitrosylation (
In conclusion, S-FLOS is a selective and sensitive assay to detect endogenous S-nitrosylation. It provides direct quantification in 2D electrophoresis applications which is not possible with any other S-nitrosylation assay described to date, while bypassing streptavidin affinity purification steps. Because the Cy-maleimide dyes label all nitrosylated protein there will be no mass shift between Cy dye and silver stain images. While S-FLOS can identify changes in S-nitrosylation, it currently does not distinguish between changes in protein expression versus changes in the number(s) of modified cysteines. In order to achieve this, a second method, such as a traditional DIGE gel21, must be performed to determine relative changes in protein expression. Finally, S-FLOS can be used for in situ detection of S-nitrosothiols in intact cell and tissue samples, which is in good agreement with other fluorescent methods demonstrated to date12,13. This method has great potential for directly mapping S-nitrosylation sites and opens up other chromatography based applications. However, merely being able to detect quantitative differences between samples on a single 2D gel will provide extremely useful information on quantitative, spatial, and temporal changes in S-nitrosylation.
References cited herein are listed below for convenience and are hereby incorporated by reference.
Number | Date | Country | Kind |
---|---|---|---|
60845944 | Sep 2006 | US | national |
The work leading to this invention was supported by grants from the U.S. Government, NIH RO1 AG 021543 from the National Institutes of Health and the National Heart, Lung, and Blood Institute (contract N01-HV-28180). The U.S. Government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US07/20328 | 9/20/2007 | WO | 00 | 4/24/2009 |